The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Beta-lactam and Beta-lactamase Inhibitors Market Outlook 2024

Global Beta-lactam and Beta-lactamase Inhibitors Market Outlook 2024

Publishing Date : Dec, 2021

License Type :
 

Report Code : 1635069

No of Pages : 129

Ask Your Query

Synopsis
β-Lactams are the most widely used class of antibiotics. Since the discovery of benzylpenicillin in the 1920s, thousands of new penicillin derivatives and related β-lactam classes of cephalosporins, cephamycins, monobactams, and carbapenems have been discovered. Each new class of b-lactam has been developed either to increase the spectrum of activity to include additional bacterial species or to address specific resistance mechanisms that have arisen in the targeted bacterial population. Resistance to β-lactams is primarily because of bacterially produced β-lactamase enzymes that hydrolyze the β-lactam ring, thereby inactivating the drug. The newest effort to circumvent resistance is the development of novel broad-spectrum β-lactamase inhibitors that work against many problematic β-lactamases, including cephalosporinases and serine-based carbapenemases, which severely limit therapeutic options.

In the global market, the core manufacturers of Beta-lactam and Beta-lactamase Inhibitors include Pfizer and Novartis (Sandoz) etc, and the top 2 manufacturers account for about 10% of the market share. The market include Asia Pacific, Europe and North America, with a share of 33%, 32% and 28%. cephalosporins accounted for 28% and penicillins accounted for 17%. The product is mainly used in intravenous and oral, with a share of 65% and 35%.

The global Beta-lactam and Beta-lactamase Inhibitors market was valued at US$ 23720 million in 2020 and is expected to reach US$ 31780 million by the end of 2027, growing at a CAGR of 1.9% during 2021-2027.

This report focuses on Beta-lactam and Beta-lactamase Inhibitors volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Beta-lactam and Beta-lactamase Inhibitors market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Beta-lactam and Beta-lactamase Inhibitors Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

  • Penicillins
  • Cephalosporins
  • Carbapenems
  • Monobactams
  • Combinations

Segment by Application

  • Oral
  • Intravenous

By Region

  • North America (United States, Canada, Mexico)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, Other Regions)
  • Europe (Germany, U.K., France, Italy, Russia, Rest of Europe)
  • South America (Brazil, Argentina, Rest of South America)
  • Middle East & Africa (Turkey, Saudi Arabia, U.A.E., South Africa, Other Regions)

By Company

  • Pfizer
  • Novartis (Sandoz)
  • Teva
  • Merck
  • Abbvie (Allergan)
  • Sumitomo Dainippon
  • Hikma
  • Aurobindo Pharma
  • Wockhardt
  • Lupin Limited
  • Fresenius Kabi
  • B. Braun
  • Usantibiotics
  • Qilu Pharmaceutical
  • Acs Dobfar
  • Nichi-Iko (Sagent)
  • Antibiotice

Scope of the Beta-lactam and Beta-lactamase Inhibitors Market Report

Report Metric

Details

Report Name

Beta-lactam and Beta-lactamase Inhibitors Market

Market size in 2020

US$ 23720 Million

The revenue forecast in 2027

US$ 31780 Million

Growth Rate

CAGR of 1.9% from 2021 to 2027

Market size available for years

2020-2027

Forecast units

Value (USD) & Volume (Units)

Segments covered

Types, End-User / Applications, Companies, and Region

Report coverage

Revenue & volume forecast, company share, competitive landscape, growth factors, and trends

Geographic regions covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

Index

1 Beta-lactam and Beta-lactamase Inhibitors Market Overview
1.1 Product Overview and Scope of Beta-lactam and Beta-lactamase Inhibitors
1.2 Beta-lactam and Beta-lactamase Inhibitors Segment by Type
1.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Penicillins
1.2.3 Cephalosporins
1.2.4 Carbapenems
1.2.5 Monobactams
1.2.6 Combinations
1.3 Beta-lactam and Beta-lactamase Inhibitors Segment by Application
1.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Comparison by Application: (2021-2027)
1.3.2 Oral
1.3.3 Intravenous
1.4 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Beta-lactam and Beta-lactamase Inhibitors Revenue 2016-2027
1.4.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales 2016-2027
1.4.3 Beta-lactam and Beta-lactamase Inhibitors Market Size by Region: 2016 Versus 2021 Versus 2027

2 Beta-lactam and Beta-lactamase Inhibitors Market Competition by Manufacturers
2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Manufacturers (2016-2021)
2.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Beta-lactam and Beta-lactamase Inhibitors Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Beta-lactam and Beta-lactamase Inhibitors Manufacturing Sites, Area Served, Product Type
2.5 Beta-lactam and Beta-lactamase Inhibitors Market Competitive Situation and Trends
2.5.1 Beta-lactam and Beta-lactamase Inhibitors Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Beta-lactam and Beta-lactamase Inhibitors Players Market Share by Revenue
2.5.3 Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Beta-lactam and Beta-lactamase Inhibitors Retrospective Market Scenario by Region
3.1 Global Beta-lactam and Beta-lactamase Inhibitors Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Beta-lactam and Beta-lactamase Inhibitors Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Country
3.3.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country
3.3.2 North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Country
3.4.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country
3.4.2 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Region
3.5.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Region
3.5.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Country
3.6.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Country
3.6.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Country
3.7.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country
3.7.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Beta-lactam and Beta-lactamase Inhibitors Historic Market Analysis by Type
4.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Type (2016-2021)
4.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Type (2016-2021)
4.3 Global Beta-lactam and Beta-lactamase Inhibitors Price by Type (2016-2021)

5 Global Beta-lactam and Beta-lactamase Inhibitors Historic Market Analysis by Application
5.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Application (2016-2021)
5.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Application (2016-2021)
5.3 Global Beta-lactam and Beta-lactamase Inhibitors Price by Application (2016-2021)

6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Pfizer Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Novartis (Sandoz)
6.2.1 Novartis (Sandoz) Corporation Information
6.2.2 Novartis (Sandoz) Description and Business Overview
6.2.3 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
6.2.5 Novartis (Sandoz) Recent Developments/Updates
6.3 TEVA
6.3.1 TEVA Corporation Information
6.3.2 TEVA Description and Business Overview
6.3.3 TEVA Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.3.4 TEVA Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
6.3.5 TEVA Recent Developments/Updates
6.4 Merck
6.4.1 Merck Corporation Information
6.4.2 Merck Description and Business Overview
6.4.3 Merck Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Merck Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
6.4.5 Merck Recent Developments/Updates
6.5 AbbVie (Allergan)
6.5.1 AbbVie (Allergan) Corporation Information
6.5.2 AbbVie (Allergan) Description and Business Overview
6.5.3 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.5.4 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
6.5.5 AbbVie (Allergan) Recent Developments/Updates
6.6 Sumitomo Dainippon
6.6.1 Sumitomo Dainippon Corporation Information
6.6.2 Sumitomo Dainippon Description and Business Overview
6.6.3 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
6.6.5 Sumitomo Dainippon Recent Developments/Updates
6.7 Hikma
6.6.1 Hikma Corporation Information
6.6.2 Hikma Description and Business Overview
6.6.3 Hikma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Hikma Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
6.7.5 Hikma Recent Developments/Updates
6.8 Aurobindo Pharma
6.8.1 Aurobindo Pharma Corporation Information
6.8.2 Aurobindo Pharma Description and Business Overview
6.8.3 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
6.8.5 Aurobindo Pharma Recent Developments/Updates
6.9 Wockhardt
6.9.1 Wockhardt Corporation Information
6.9.2 Wockhardt Description and Business Overview
6.9.3 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
6.9.5 Wockhardt Recent Developments/Updates
6.10 Lupin Limited
6.10.1 Lupin Limited Corporation Information
6.10.2 Lupin Limited Description and Business Overview
6.10.3 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
6.10.5 Lupin Limited Recent Developments/Updates
6.11 Fresenius Kabi
6.11.1 Fresenius Kabi Corporation Information
6.11.2 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Description and Business Overview
6.11.3 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
6.11.5 Fresenius Kabi Recent Developments/Updates
6.12 B. Braun
6.12.1 B. Braun Corporation Information
6.12.2 B. Braun Beta-lactam and Beta-lactamase Inhibitors Description and Business Overview
6.12.3 B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.12.4 B. Braun Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
6.12.5 B. Braun Recent Developments/Updates
6.13 USantibiotics
6.13.1 USantibiotics Corporation Information
6.13.2 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Description and Business Overview
6.13.3 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.13.4 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
6.13.5 USantibiotics Recent Developments/Updates
6.14 Qilu Pharmaceutical
6.14.1 Qilu Pharmaceutical Corporation Information
6.14.2 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Description and Business Overview
6.14.3 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
6.14.5 Qilu Pharmaceutical Recent Developments/Updates
6.15 ACS Dobfar
6.15.1 ACS Dobfar Corporation Information
6.15.2 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Description and Business Overview
6.15.3 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.15.4 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
6.15.5 ACS Dobfar Recent Developments/Updates
6.16 Nichi-Iko (Sagent)
6.16.1 Nichi-Iko (Sagent) Corporation Information
6.16.2 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Description and Business Overview
6.16.3 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.16.4 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
6.16.5 Nichi-Iko (Sagent) Recent Developments/Updates
6.17 Antibiotice
6.17.1 Antibiotice Corporation Information
6.17.2 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Description and Business Overview
6.17.3 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
6.17.4 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
6.17.5 Antibiotice Recent Developments/Updates

7 Beta-lactam and Beta-lactamase Inhibitors Manufacturing Cost Analysis
7.1 Beta-lactam and Beta-lactamase Inhibitors Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Beta-lactam and Beta-lactamase Inhibitors
7.4 Beta-lactam and Beta-lactamase Inhibitors Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Beta-lactam and Beta-lactamase Inhibitors Distributors List
8.3 Beta-lactam and Beta-lactamase Inhibitors Customers

9 Beta-lactam and Beta-lactamase Inhibitors Market Dynamics
9.1 Beta-lactam and Beta-lactamase Inhibitors Industry Trends
9.2 Beta-lactam and Beta-lactamase Inhibitors Growth Drivers
9.3 Beta-lactam and Beta-lactamase Inhibitors Market Challenges
9.4 Beta-lactam and Beta-lactamase Inhibitors Market Restraints

10 Global Market Forecast
10.1 Beta-lactam and Beta-lactamase Inhibitors Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Beta-lactam and Beta-lactamase Inhibitors by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Beta-lactam and Beta-lactamase Inhibitors by Type (2022-2027)
10.2 Beta-lactam and Beta-lactamase Inhibitors Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Beta-lactam and Beta-lactamase Inhibitors by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Beta-lactam and Beta-lactamase Inhibitors by Application (2022-2027)
10.3 Beta-lactam and Beta-lactamase Inhibitors Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Beta-lactam and Beta-lactamase Inhibitors by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Beta-lactam and Beta-lactamase Inhibitors by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Tables

List of Tables
Table 1. Global Beta-lactam and Beta-lactamase Inhibitors Sales (M Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Beta-lactam and Beta-lactamase Inhibitors Sales (M Units) Comparison by Application (2021-2027)
Table 3. Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Beta-lactam and Beta-lactamase Inhibitors Covered in This Study
Table 5. Global Beta-lactam and Beta-lactamase Inhibitors Sales (M Units) of Key Manufacturers (2016-2021)
Table 6. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Beta-lactam and Beta-lactamase Inhibitors Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Beta-lactam and Beta-lactamase Inhibitors Average Price (US$/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Beta-lactam and Beta-lactamase Inhibitors Manufacturing Sites and Area Served
Table 11. Manufacturers Beta-lactam and Beta-lactamase Inhibitors Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Beta-lactam and Beta-lactamase Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Beta-lactam and Beta-lactamase Inhibitors as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2016-2021) & (M Units)
Table 16. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Region (2016-2021)
Table 17. Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2016-2021) & (M Units)
Table 19. North America Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2016-2021)
Table 20. North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Country (2016-2021)
Table 22. Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2016-2021) & (M Units)
Table 23. Europe Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2016-2021)
Table 24. Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2016-2021) & (M Units)
Table 27. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Region (2016-2021)
Table 30. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2016-2021) & (M Units)
Table 31. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2016-2021)
Table 32. Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2016-2021) & (M Units)
Table 35. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Country (2016-2021)
Table 38. Global Beta-lactam and Beta-lactamase Inhibitors Sales (M Units) by Type (2016-2021)
Table 39. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Type (2016-2021)
Table 40. Global Beta-lactam and Beta-lactamase Inhibitors Revenue (Million US$) by Type (2016-2021)
Table 41. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Share by Type (2016-2021)
Table 42. Global Beta-lactam and Beta-lactamase Inhibitors Price (US$/Unit) by Type (2016-2021)
Table 43. Global Beta-lactam and Beta-lactamase Inhibitors Sales (M Units) by Application (2016-2021)
Table 44. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Application (2016-2021)
Table 45. Global Beta-lactam and Beta-lactamase Inhibitors Revenue (Million US$) by Application (2016-2021)
Table 46. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Share by Application (2016-2021)
Table 47. Global Beta-lactam and Beta-lactamase Inhibitors Price (US$/Unit) by Application (2016-2021)
Table 48. Pfizer Corporation Information
Table 49. Pfizer Description and Business Overview
Table 50. Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 51. Pfizer Beta-lactam and Beta-lactamase Inhibitors Product
Table 52. Pfizer Recent Developments/Updates
Table 53. Novartis (Sandoz) Corporation Information
Table 54. Novartis (Sandoz) Description and Business Overview
Table 55. Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 56. Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Product
Table 57. Novartis (Sandoz) Recent Developments/Updates
Table 58. TEVA Corporation Information
Table 59. TEVA Description and Business Overview
Table 60. TEVA Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 61. TEVA Beta-lactam and Beta-lactamase Inhibitors Product
Table 62. TEVA Recent Developments/Updates
Table 63. Merck Corporation Information
Table 64. Merck Description and Business Overview
Table 65. Merck Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 66. Merck Beta-lactam and Beta-lactamase Inhibitors Product
Table 67. Merck Recent Developments/Updates
Table 68. AbbVie (Allergan) Corporation Information
Table 69. AbbVie (Allergan) Description and Business Overview
Table 70. AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 71. AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Product
Table 72. AbbVie (Allergan) Recent Developments/Updates
Table 73. Sumitomo Dainippon Corporation Information
Table 74. Sumitomo Dainippon Description and Business Overview
Table 75. Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 76. Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Product
Table 77. Sumitomo Dainippon Recent Developments/Updates
Table 78. Hikma Corporation Information
Table 79. Hikma Description and Business Overview
Table 80. Hikma Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 81. Hikma Beta-lactam and Beta-lactamase Inhibitors Product
Table 82. Hikma Recent Developments/Updates
Table 83. Aurobindo Pharma Corporation Information
Table 84. Aurobindo Pharma Description and Business Overview
Table 85. Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 86. Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Product
Table 87. Aurobindo Pharma Recent Developments/Updates
Table 88. Wockhardt Corporation Information
Table 89. Wockhardt Description and Business Overview
Table 90. Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 91. Wockhardt Beta-lactam and Beta-lactamase Inhibitors Product
Table 92. Wockhardt Recent Developments/Updates
Table 93. Lupin Limited Corporation Information
Table 94. Lupin Limited Description and Business Overview
Table 95. Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 96. Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Product
Table 97. Lupin Limited Recent Developments/Updates
Table 98. Fresenius Kabi Corporation Information
Table 99. Fresenius Kabi Description and Business Overview
Table 100. Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 101. Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Product
Table 102. Fresenius Kabi Recent Developments/Updates
Table 103. B. Braun Corporation Information
Table 104. B. Braun Description and Business Overview
Table 105. B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 106. B. Braun Beta-lactam and Beta-lactamase Inhibitors Product
Table 107. B. Braun Recent Developments/Updates
Table 108. USantibiotics Corporation Information
Table 109. USantibiotics Description and Business Overview
Table 110. USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 111. USantibiotics Beta-lactam and Beta-lactamase Inhibitors Product
Table 112. USantibiotics Recent Developments/Updates
Table 113. Qilu Pharmaceutical Corporation Information
Table 114. Qilu Pharmaceutical Description and Business Overview
Table 115. Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 116. Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Product
Table 117. Qilu Pharmaceutical Recent Developments/Updates
Table 118. ACS Dobfar Corporation Information
Table 119. ACS Dobfar Description and Business Overview
Table 120. ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 121. ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Product
Table 122. ACS Dobfar Recent Developments/Updates
Table 123. Nichi-Iko (Sagent) Corporation Information
Table 124. Nichi-Iko (Sagent) Description and Business Overview
Table 125. Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 126. Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Product
Table 127. Nichi-Iko (Sagent) Recent Developments/Updates
Table 128. Antibiotice Corporation Information
Table 129. Antibiotice Description and Business Overview
Table 130. Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 131. Antibiotice Beta-lactam and Beta-lactamase Inhibitors Product
Table 132. Antibiotice Recent Developments/Updates
Table 133. Production Base and Market Concentration Rate of Raw Material
Table 134. Key Suppliers of Raw Materials
Table 135. Beta-lactam and Beta-lactamase Inhibitors Distributors List
Table 136. Beta-lactam and Beta-lactamase Inhibitors Customers List
Table 137. Beta-lactam and Beta-lactamase Inhibitors Market Trends
Table 138. Beta-lactam and Beta-lactamase Inhibitors Growth Drivers
Table 139. Beta-lactam and Beta-lactamase Inhibitors Market Challenges
Table 140. Beta-lactam and Beta-lactamase Inhibitors Market Restraints
Table 141. Global Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Type (2022-2027) & (M Units)
Table 142. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share Forecast by Type (2022-2027)
Table 143. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 144. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share Forecast by Type (2022-2027)
Table 145. Global Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Application (2022-2027) & (M Units)
Table 146. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share Forecast by Application (2022-2027)
Table 147. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 148. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share Forecast by Application (2022-2027)
Table 149. Global Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Region (2022-2027) & (M Units)
Table 150. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share Forecast by Region (2022-2027)
Table 151. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 152. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share Forecast by Region (2022-2027)
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Beta-lactam and Beta-lactamase Inhibitors
Figure 2. Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Type in 2020 & 2027
Figure 3. Penicillins Product Picture
Figure 4. Cephalosporins Product Picture
Figure 5. Carbapenems Product Picture
Figure 6. Monobactams Product Picture
Figure 7. Combinations Product Picture
Figure 8. Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Application in 2020 & 2027
Figure 9. Oral
Figure 10. Intravenous
Figure 11. Global Beta-lactam and Beta-lactamase Inhibitors Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Beta-lactam and Beta-lactamase Inhibitors Market Size 2016-2027 (US$ Million)
Figure 13. Global Beta-lactam and Beta-lactamase Inhibitors Sales 2016-2027 (M Units)
Figure 14. Global Beta-lactam and Beta-lactamase Inhibitors Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 15. Beta-lactam and Beta-lactamase Inhibitors Sales Share by Manufacturers in 2020
Figure 16. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Share by Manufacturers in 2020
Figure 17. The Global 5 and 10 Largest Beta-lactam and Beta-lactamase Inhibitors Players: Market Share by Revenue in 2020
Figure 18. Beta-lactam and Beta-lactamase Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 19. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Region (2016-2021)
Figure 20. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Region in 2020
Figure 21. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Region (2016-2021)
Figure 22. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Region in 2020
Figure 23. United States Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. Canada Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Germany Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. France Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. U.K. Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Italy Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Russia Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. China Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Japan Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. South Korea Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. India Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Australia Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. China Taiwan Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Indonesia Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Thailand Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Malaysia Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Mexico Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Brazil Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Argentina Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Turkey Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Saudi Arabia Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. UAE Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Sales Market Share of Beta-lactam and Beta-lactamase Inhibitors by Type (2016-2021)
Figure 46. Sales Market Share of Beta-lactam and Beta-lactamase Inhibitors by Application (2016-2021)
Figure 47. Sales Market Share of Beta-lactam and Beta-lactamase Inhibitors by Application in 2020
Figure 48. Revenue Share of Beta-lactam and Beta-lactamase Inhibitors by Application (2016-2021)
Figure 49. Revenue Share of Beta-lactam and Beta-lactamase Inhibitors by Application in 2020
Figure 50. Manufacturing Cost Structure of Beta-lactam and Beta-lactamase Inhibitors
Figure 51. Manufacturing Process Analysis of Beta-lactam and Beta-lactamase Inhibitors
Figure 52. Beta-lactam and Beta-lactamase Inhibitors Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Latest Life Science Market Reports

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock